HEI Logo

Formerly the Department of Clinical Epidemiology and Biostatistics (CE&B)

Welcome to the Department of Health Research Methods, Evidence, and Impact (HEI), formerly the Department of Clinical Epidemiology and Biostatistics (CE&B). Recognizing that the CE&B name captured only some of the depth and breadth of disciplines and expertise in the department, we formally changed its name effective January 1, 2017.

The name is outcomes focused: we produce, synthesize, package, share, and support the best available research evidence in the health and health-related fields, and we undertake a variety of initiatives designed to achieve impacts at all levels within as well as across health systems. The name effectively connects us to the department's history in evidence-based medicine and the global impact that this and other departmental initiatives have had. Moreover, the new name captures the department's strategic goal of extending its leadership in developing new health research methods, generating and synthesizing actionable research evidence, and achieving impact.




HEI welcomes your enquiries, requests, comments, suggestions and proposals. Please contact the Chair at chairhei@mcmaster.ca

New recommendations on antiretroviral drugs for pregnant women living with HIV can help women make more informed choices about benefits and harms, according to a panel of international experts.

The recommendations, which take a patient's perspective rather than a public health perspective, differ from current guidelines, and are meant to support shared decision making between pregnant women and their health-care provider, say the authors.

The new guidelines suggest that most women are likely to prefer older HIV medications rather than the ones that are most often currently prescribed.

The paper was recently published in The BMJ as part of its Rapid Recommendations series.

The Rapid Recommendations series lead and first author of the guidelines is Reed Siemieniuk, a physician and a PhD student in the Department of Health Research Methods, Evidence, and Impact at McMaster University.   

Every year about 1.4 million women living with HIV become pregnant. Most women take a combination of three antiretroviral drugs to reduce the risk of transmission to their child or for personal health reasons.

Recent trial evidence suggested that the most commonly used drug combinations might increase the risk of premature birth and neonatal death compared with other drug combinations.

An international panel - made up of women living with HIV, specialist doctors, and general practitioners - carried out a detailed analysis of the evidence to make recommendations.

Their suggestions are based on data from two systematic reviews, published in BMJ Open, that looked at the benefits and harms of different drug combinations for pregnant women with HIV and the values and preferences of women considering antiretroviral therapy.

Evidence from these reviews led the panel to recommend older alternatives instead of the most widely used drug combinations to help reduce the risk of premature birth and neonatal death – which almost all women said they were extremely keen to avoid.

The panel acknowledge that the number of antiretroviral therapy options that women can choose from and can be prescribed varies considerably throughout the world - and that, in many settings, alternative drugs may not be available.

They also point out that their recommendations, like all BMJ Rapid Recommendations, take a patient centred perspective. Whereas guidelines that take a public health perspective, such as the WHO guideline, need to consider resource use and might make different recommendations based on the same evidence.

The panel recognizes the operational challenges that alternative treatment options may introduce, particularly in low resource settings.

In conclusion, they say there is a lack of reliable trial data on the safety and efficacy of most commonly used combination antiretroviral therapy in pregnant women living with HIV.

They call for further research to inform treatment options, as well as efforts to overcome operational challenges "so that availability of the right choice of combination antiretroviral therapy is aligned with the best available evidence for almost all pregnant women living with HIV."